Innovative Treatment Flyte offers a clinically proven, FDA-cleared in-home treatment for female urinary incontinence, positioning it as a leading conservative solution that appeals to women seeking effective yet non-invasive options.

Recent Product Launches The launch of the next generation Flyte System in December 2024 provides opportunities to promote upgraded features and tools, attracting healthcare providers and patients looking for the latest advancements in pelvic health therapy.

Growing Financial Backing With multiple funding rounds totaling over $10 million, Pelvital demonstrates strong investor confidence, indicating potential resources to expand sales outreach, enhance marketing efforts, and grow user adoption.

Market Potential Operating within a revenue range of $1 million to $10 million, the company is positioned in a high-growth segment of women's health, offering substantial potential for partnerships with clinics, hospitals, and medical device distributors.

Strategic Leadership The recent appointment of a seasoned healthcare executive to the board and active funding initiatives highlight the company’s focus on scaling operations and increasing market penetration, ideal for sales collaborations focused on expansion.